MUMBAI, India, June 27 -- Intellectual Property India has published a patent application (202518050970 A) filed by Amgen Inc., Thousand Oaks, U.S.A., on May 27, for 'improved synthesis of kras g12c inhibitor compound.'
Inventor(s) include Parsons, Andrew T.; and Beaver, Matthew.
The application for the patent was published on June 27, under issue no. 26/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2',2''-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3- 5 fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers. Compound 9."
The patent application was internationally filed on Nov. 13, 2020, under International application No.PCT/US2020/060421.
Disclaimer: Curated by HT Syndication.
